The episode also ventures into his post-Pfizer endeavors in biotech, where Dr. LaMattina supports innovative ventures in areas like the microbiome and schizophrenia treatment through PureTech Health. He addresses current industry challenges, including drug pricing pressures and the significance of ongoing innovation, emphasizing the critical role of biotechnology and pharma in advancing healthcare. The conversation covers key factors in fostering innovation, the impact of venture capital on drug development, and the pressing need for public understanding and appreciation of the biopharmaceutical industry's contributions.